| Status | Suspended |
| Decision | Selected |
| Process | STA pre-2018 |
| Referral date | 01 June 2008 |
| Topic area |
|
Provisional Schedule
| Closing date for invited submissions / evidence submission: | TBC |
| 1st appraisal committee meeting: | TBC |
Project Team
| Assessment Group / Evidence Review Group: | TBC |
| Communications manager: | TBC |
| Executive Lead: | TBC |
| Project manager: | TBC |
| Technical Lead: | TBC |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 19 February 2010 |
The manufacturer of temozolomide has advised us that regulatory approval for this technology is not being sought at the present time. The Institute has therefore decided to remove this appraisal from its current work programme. As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes. If you have any comments or concerns please do not hesitate to contact the Project Manager for this appraisal, Cathryn Hall (020 7045 2240 or email: cathryn.hall@nice.org.uk) |
For further information on our processes and methods, please see our CHTE processes and methods manual